Salinas Pita Angela Patricia, Mosquera Escudero Mildrey, Jiménez-Charris Eliecer, García-Perdomo Herney Andrés
Program in Biomedical Sciences, Universidad del Valle, Cali, Colombia.
Department of Physiological Sciences, Basic Science School, Nutrition Group, Universidad del Valle, Cali, Colombia.
J Cancer Res Clin Oncol. 2024 Dec 31;151(1):29. doi: 10.1007/s00432-024-06058-w.
To determine the association of a metabolomic profile with the diagnosis of localized prostate cancer.
We conducted a search strategy in MEDLINE (OVID), EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials (CENTRAL) from 2008 to the present. We included Clinical trials and analytical and descriptive observational studies that reported metabolite results and metabolite profiles in serum, tissue, urine, and seminal fluid. All studies used metabolomic techniques such as MS and MRI to identify patients with localized prostate cancer compared with patients without cancer. We used QUADAS 2 to assess the risk of bias.
We found 1248 studies with the search strategy. Finally, 14 case-control studies were included. Serum was the primary sample to identify the metabolites. Low concern was found regarding applying the index test and the reference standard in assessing the risk of bias. The metabolites of interest associated with establishing a metabolomic profile in the diagnosis of localized prostate cancer were amino acids, lipids, androgens, estrogens, nucleotides, and histidine metabolism.
Disturbances in the metabolism of fatty acids, amino acids, nucleotides, and steroid hormones were identified, suggesting the presence of localized prostate cancer. Importantly, serum samples showed an increase in amino acid levels. Glutamate and aspartic acid stand out among the amino acids that register high levels. In addition, glycine and serine were consistently decreased metabolites in the three kinds of biological samples analyzed.
确定代谢组学特征与局限性前列腺癌诊断之间的关联。
我们在2008年至今的MEDLINE（OVID）、EMBASE、LILACS以及Cochrane对照试验中央注册库（CENTRAL）中进行了检索。我们纳入了报告血清、组织、尿液和精液中代谢物结果及代谢物谱的临床试验、分析性和描述性观察性研究。所有研究均使用质谱（MS）和磁共振成像（MRI）等代谢组学技术来鉴别局限性前列腺癌患者与无癌患者。我们使用QUADAS 2评估偏倚风险。
通过检索策略我们找到1248项研究。最终，纳入了14项病例对照研究。血清是用于鉴定代谢物的主要样本。在评估偏倚风险时，对于应用指标检测和参考标准的关注较低。与建立局限性前列腺癌诊断的代谢组学特征相关的感兴趣的代谢物包括氨基酸、脂质、雄激素、雌激素、核苷酸以及组氨酸代谢。
已确定脂肪酸、氨基酸、核苷酸和类固醇激素代谢存在紊乱，提示存在局限性前列腺癌。重要的是，血清样本显示氨基酸水平升高。谷氨酸和天冬氨酸在高水平的氨基酸中较为突出。此外，甘氨酸和丝氨酸在分析的三种生物样本中始终是降低的代谢物。
